Developer docs
API playgroundTry for free, no card

Search company profiles

Lavie bio

Full company profile

uuid00029k8

Namestring
Lavie bio
Legal namestring
Lavie Bio Ltd.
Websiteurl
lavie-bio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Lavie Bio Ltd. was an Israeli agritech company headquartered in Rehovot that developed agricultural biologicals — specifically biostimulants and biopesticides — using beneficial bacteria formulations. The company's core offering centered on its patented MicroFermentor technology, a microbe formulation approach that enables bacteria to multiply directly on the plant, which the company claimed reduces application costs, extends shelf life, and improves post-application viability relative to conventional bioinoculant delivery. Lavie Bio leveraged the MicroBoost AI computational biology platform, developed by parent company Evogene, to identify microbial candidates and predict product performance, allowing the company to position itself at the intersection of synthetic biology and AI-driven screening.

Lavie Bio was founded in 2019 as a subsidiary of Evogene Ltd. with $27 million in initial capital, later raising $10 million from ICL Planet Startup Hub in 2022 and receiving a non-dilutive Israel Innovation Authority grant in September 2024 to advance MicroFermentor toward commercialization. The company employed between 11 and 50 people and served a single vertical — farmers and agricultural operations — though no specific customer logos, pricing models, or distribution channels were publicly disclosed, suggesting the business remained in a pre-commercial or pilot stage throughout its independent existence.

In 2025, Lavie Bio's activity was acquired by ICL Group Ltd., a specialty chemicals manufacturer pursuing strategic expansion into agricultural biologicals, through a divestiture by Evogene that was part of Evogene's broader shift to focus on its ChemPass AI platform. Evogene subsequently reported discontinuing the Lavie Bio subsidiary in Q1 2026, indicating the standalone entity was wound down and its assets and capabilities integrated into ICL's ag-biologicals business. Lavie Bio operated as a private, Israel-domiciled limited company throughout its existence with no public listing.

Short descriptiontext

Lavie Bio was an Israeli agritech company developing agricultural biologicals — biostimulants and biopesticides — using its patented MicroFermentor bacteria technology and Evogene's MicroBoost AI platform. Founded in 2019, it served farmers seeking sustainable crop solutions before its 2025 acquisition by ICL Group and subsequent discontinuation as a standalone entity.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRehovot, Israel
HQ citystring
Rehovot
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
agricultural biologicals, microbial biostimulants, biopesticide solutions, beneficial bacteria, crop enhancement
Industry2 codes
1Biostimulants & Plant Health Biologicals (Microbial/Non-microbial)
CodeAFABAEAKPrimaryYes
2Biological Formulation, Fermentation & Scale-Up Manufacturing
CodeAFABAEAMPrimaryNo
NAICS code2 codes
  • Pesticide and Other Agricultural Chemical Manufacturing32532
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Agricultural Biologicals
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1MicroBoost AI
Description

AI computational biology platform used by Lavie Bio for developing microbial solutions in agriculture.

igrownews.com
+1 more record
Core offering1 text field

Lavie Bio develops and produces agricultural biological products based on proprietary microbial formulations, led by its patented MicroFermentor technology that uses beneficial bacteria to enhance crop growth. The bacteria are formulated to multiply directly on plants, reducing application costs, extending shelf life, and improving viability after field application. The company leverages AI-powered computational biology platforms (MicroBoost AI) for microbial candidate identification and biostimulant and biopesticide development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduces application costs through direct bacterial multiplication on plants
+2 more records
Product overview1 text field

Lavie Bio was an Israeli agritech company that developed biological products for sustainable agriculture, utilizing proprietary beneficial bacteria formulations. The company's primary offerings included MicroFermentor technology for microbe-based crop solutions. Lavie Bio operated as a subsidiary of Evogene, deploying its MicroBoost AI platform for product development in agricultural biologicals. In 2025, Lavie Bio's activity was acquired by ICL Group Ltd., and subsequently discontinued by Evogene as part of its strategic restructuring.

Product and service1 record
1MicroFermentor
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based developer of microbial crop protection products (biopesticides and biostimulants). Direct peer with similar proprietary microbe collection, formulation focus, and biologicals commercialization model.

TypeDirect peer
Description

Largest US ag-biologicals player using microbial seed coatings and foliar products. Direct competitor in microbial biostimulants and biopesticides with comparable go-to-market via row crop and specialty crop growers.

TypeBroad incumbent
Description

Diversified specialty ag-inputs business with biologicals offerings alongside traditional fertilizers and micronutrients. Comparable adjacency to Lavie Bio's agricultural biologicals category with established global distribution.

TypeDirect peer
Description

US-based ag-biological company developing microbial nitrogen-fixing products for major row crops. Directly comparable to Lavie Bio in microbial mode-of-action, AI-assisted discovery, and commercial focus on biostimulant-class agricultural biologicals.

TypeDirect peer
Description

US-based company developing on-demand microbial nitrogen and biostimulant products for row crops. Comparable microbial ag-biologicals positioning with overlapping grower customer profiles.

TypeDirect peer
Description

US ag-biological company commercializing pink-pigmented facultative methylotrophs (PPFMs) as biostimulants. Direct peer in microbial biostimulant category with overlapping row-crop and specialty-crop customer base.

TypeEmerging player
Description

Belgium-based ag-biological company developing protein-based biocontrol solutions. Comparable in agricultural biologicals category targeting crop protection, though using a different (protein-based) technological approach.

TypeBroad incumbent
Description

Bioceres-affiliated biologicals platform with established biopesticide and biostimulant products. Comparable in end-product category and go-to-market, broader portfolio and global scale.

TypeBroad incumbent
Description

US-listed synthetic biology platform with agricultural biologicals as a major vertical (formerly through Joyn Bio with Bayer). Comparable AI + microbial discovery model applied to ag inputs at much larger scale.

TypeEmerging player
Description

US-based ag-biological company using microbial consortia for nitrogen fixation, biocontrol, and biostimulants. Comparable technology stack and target applications, slightly earlier stage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lavie bio

Agricultural Biologicalslavie-bio.com

Lavie Bio was an Israeli agritech company developing agricultural biologicals — biostimulants and biopesticides — using its patented MicroFermentor bacteria technology and Evogene's MicroBoost AI platform. Founded in 2019, it served farmers seeking sustainable crop solutions before its 2025 acquisition by ICL Group and subsequent discontinuation as a standalone entity.

What Lavie bio does

Lavie Bio Ltd. was an Israeli agritech company headquartered in Rehovot that developed agricultural biologicals — specifically biostimulants and biopesticides — using beneficial bacteria formulations. The company's core offering centered on its patented MicroFermentor technology, a microbe formulation approach that enables bacteria to multiply directly on the plant, which the company claimed reduces application costs, extends shelf life, and improves post-application viability relative to conventional bioinoculant delivery. Lavie Bio leveraged the MicroBoost AI computational biology platform, developed by parent company Evogene, to identify microbial candidates and predict product performance, allowing the company to position itself at the intersection of synthetic biology and AI-driven screening.

Lavie Bio was founded in 2019 as a subsidiary of Evogene Ltd. with $27 million in initial capital, later raising $10 million from ICL Planet Startup Hub in 2022 and receiving a non-dilutive Israel Innovation Authority grant in September 2024 to advance MicroFermentor toward commercialization. The company employed between 11 and 50 people and served a single vertical — farmers and agricultural operations — though no specific customer logos, pricing models, or distribution channels were publicly disclosed, suggesting the business remained in a pre-commercial or pilot stage throughout its independent existence.

In 2025, Lavie Bio's activity was acquired by ICL Group Ltd., a specialty chemicals manufacturer pursuing strategic expansion into agricultural biologicals, through a divestiture by Evogene that was part of Evogene's broader shift to focus on its ChemPass AI platform. Evogene subsequently reported discontinuing the Lavie Bio subsidiary in Q1 2026, indicating the standalone entity was wound down and its assets and capabilities integrated into ICL's ag-biologicals business. Lavie Bio operated as a private, Israel-domiciled limited company throughout its existence with no public listing.

Lavie bio firmographics

Firmographics
Name
Lavie bio
Legal name
Lavie Bio Ltd.
Website
https://lavie-bio.com
Company type
Private
Founded year
2019
Operating status
Acquired
Headcount range
11–50 employees
Short description
Lavie Bio was an Israeli agritech company developing agricultural biologicals — biostimulants and biopesticides — using its patented MicroFermentor bacteria technology and Evogene's MicroBoost AI platform. Founded in 2019, it served farmers seeking sustainable crop solutions before its 2025 acquisition by ICL Group and subsequent discontinuation as a standalone entity.
Ownership category
akta.pro rank

Lavie bio industry classification

Industry
Product category
Agricultural Biologicals
NAICS
Pesticide and Other Agricultural Chemical Manufacturing (32532), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
Biostimulants & Plant Health Biologicals (Microbial/Non-microbial) (AFABAEAK)
akta.pro secondary industry
Biological Formulation, Fermentation & Scale-Up Manufacturing (AFABAEAM)

Keywords

  • Agricultural biologicals
  • Microbial biostimulants
  • Biopesticide solutions
  • Beneficial bacteria
  • Crop enhancement

Where Lavie bio is headquartered

Location

Headquarters

HQ city
Rehovot
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Lavie bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Lavie bio product offering

Product offering

Core offering

Lavie Bio develops and produces agricultural biological products based on proprietary microbial formulations, led by its patented MicroFermentor technology that uses beneficial bacteria to enhance crop growth. The bacteria are formulated to multiply directly on plants, reducing application costs, extending shelf life, and improving viability after field application. The company leverages AI-powered computational biology platforms (MicroBoost AI) for microbial candidate identification and biostimulant and biopesticide development.

Product overview

Lavie Bio was an Israeli agritech company that developed biological products for sustainable agriculture, utilizing proprietary beneficial bacteria formulations. The company's primary offerings included MicroFermentor technology for microbe-based crop solutions. Lavie Bio operated as a subsidiary of Evogene, deploying its MicroBoost AI platform for product development in agricultural biologicals. In 2025, Lavie Bio's activity was acquired by ICL Group Ltd., and subsequently discontinued by Evogene as part of its strategic restructuring.

Differentiator

Problem solved

Functional benefit

Brands

  • MicroBoost AI: AI computational biology platform used by Lavie Bio for developing microbial solutions in agriculture.
  • MicroFermentor

Products and services

  • MicroFermentor

Quantifiable outcome

  • Reduces application costs through direct bacterial multiplication on plants
  • +2 more outcomes

Companies that use Lavie bio

Customer profile

Segments1 record

Ideal customer profiles1 record

Lavie bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Lavie bio partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves8 records

Expansion highlights3 records

Lavie bio competitors and assessment

Company assessment

Direct peers

  • AgBiome: US-based developer of microbial crop protection products (biopesticides and biostimulants). Direct peer with similar proprietary microbe collection, formulation focus, and biologicals commercialization model.
  • Indigo Ag: Largest US ag-biologicals player using microbial seed coatings and foliar products. Direct competitor in microbial biostimulants and biopesticides with comparable go-to-market via row crop and specialty crop growers.
  • Pivot Bio: US-based ag-biological company developing microbial nitrogen-fixing products for major row crops. Directly comparable to Lavie Bio in microbial mode-of-action, AI-assisted discovery, and commercial focus on biostimulant-class agricultural biologicals.
  • Sound Agriculture: US-based company developing on-demand microbial nitrogen and biostimulant products for row crops. Comparable microbial ag-biologicals positioning with overlapping grower customer profiles.
  • NewLeaf Symbiotics: US ag-biological company commercializing pink-pigmented facultative methylotrophs (PPFMs) as biostimulants. Direct peer in microbial biostimulant category with overlapping row-crop and specialty-crop customer base.

Broad incumbents

  • Koch Agronomic Services: Diversified specialty ag-inputs business with biologicals offerings alongside traditional fertilizers and micronutrients. Comparable adjacency to Lavie Bio's agricultural biologicals category with established global distribution.
  • Marrone Bio Innovations (Bioceres Crop Solutions): Bioceres-affiliated biologicals platform with established biopesticide and biostimulant products. Comparable in end-product category and go-to-market, broader portfolio and global scale.
  • Ginkgo Bioworks: US-listed synthetic biology platform with agricultural biologicals as a major vertical (formerly through Joyn Bio with Bayer). Comparable AI + microbial discovery model applied to ag inputs at much larger scale.

Emerging players

  • Biotalys: Belgium-based ag-biological company developing protein-based biocontrol solutions. Comparable in agricultural biologicals category targeting crop protection, though using a different (protein-based) technological approach.
  • BioConsortia: US-based ag-biological company using microbial consortia for nitrogen fixation, biocontrol, and biostimulants. Comparable technology stack and target applications, slightly earlier stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Lavie bio social profiles

Digital presence

Lavie bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lavie bio leadership team

Management profile

Number of profiles

Profiles1 record

Lavie bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lavie bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lavie bio

What does Lavie bio do?

Lavie Bio develops and produces agricultural biological products based on proprietary microbial formulations, led by its patented MicroFermentor technology that uses beneficial bacteria to enhance crop growth. The bacteria are formulated to multiply directly on plants, reducing application costs, extending shelf life, and improving viability after field application. The company leverages AI-powered computational biology platforms (MicroBoost AI) for microbial candidate identification and biostimulant and biopesticide development.

Is Lavie bio a public or private company?

Lavie bio is a private company. It is classified as corporate owned and is currently acquired.

When was Lavie bio founded?

Lavie bio was founded in 2019. It employs 11 to 50 people.

Where is Lavie bio based?

Lavie bio is headquartered in Rehovot, Israel, in the Middle East region.

Who are Lavie bio's main competitors?

Direct peers on record are AgBiome, Indigo Ag, Pivot Bio, Sound Agriculture and NewLeaf Symbiotics. Broad incumbents are Koch Agronomic Services, Marrone Bio Innovations (Bioceres Crop Solutions) and Ginkgo Bioworks. Emerging players are Biotalys and BioConsortia.

Does Lavie bio have an API?

No public API is recorded for Lavie bio.

What industry is Lavie bio in?

Lavie bio's product category is Agricultural Biologicals. Its primary akta.pro industry code is AFABAEAK, Biostimulants & Plant Health Biologicals (Microbial/Non-microbial), with a secondary code of AFABAEAM, Biological Formulation, Fermentation & Scale-Up Manufacturing. Its NAICS code is 32532 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireEvogene Reports Second Quarter and First Half 2026 Financial ResultsEvogene reported Q2 2026 net loss of about $1.8 million, down from $4.7 million in Q2 2025, and expects full-year 2026 cash usage of $8.5–9.5 million. The company also expanded its virtual chemical space to about 110 billion molecules and advanced its internal drug discovery program.AgriBusiness GlobalThe Future of Biologicals FormulationThe article examines how artificial intelligence is reshaping the agricultural biologicals industry by accelerating product discovery, improving formulation consistency, and reducing development timelines. Key collaborations including Syngenta's partnerships with AI specialist InstaDeep and machine-learning firm TraitSeq, along with ICL's acquisition of Lavie Bio and its MicroBoost AI platform, illustrate how companies are leveraging AI to identify microbial candidates and predict product performance for biostimulants and biopesticides. While AI integration offers commercial advantages through faster time-to-market and improved product consistency, the article notes that challenges remain around data standardization and the need for field validation of computational predictions.SyngentaSyngenta and Lavie Bio announce partnership to discover and develop novel bio-insecticideSyngenta Crop Protection and Lavie Bio announced a partnership to discover and develop novel bio-insecticidal solutions. The collaboration leverages Lavie Bio's computational technology platform alongside Syngenta's global research and commercialization capabilities to address crop damage caused by insects.Icl-PlanetCircular Economy Investments: How CVCs Drive Recycling and Upcycling InnovationThe article outlines the strategic role of Corporate Venture Capital (CVC) arms, specifically highlighting ICL Planet's investments in circular economy technologies such as recycling and upcycling innovations. It details how CVCs accelerate market entry for startups by providing not just capital but also industrial validation and go-to-market support, citing examples like the acquisition of Lavie Bio by ICL Group. The piece emphasizes that integrating ESG principles into investment criteria offers a strategic advantage in transitioning towards sustainable, waste-free industrial ecosystems.AgriBusiness GlobalTop 15 Biologicals Insights: Markets, Technology, and Growth OpportunitiesLeading agribusiness companies including Syngenta, Corteva, Bayer, and ICL are accelerating investments in agricultural biologicals through new manufacturing facilities, acquisitions, and strategic partnerships. Syngenta opened a 16,000-ton annual capacity production facility in South Carolina, while ICL acquired Lavie Bio to expand its biologicals portfolio using AI-powered technology. The market is transitioning from niche to mainstream, though challenges around scalability, market saturation, and grower trust persist in regions like Brazil and LATAM.PR NewswireEvogene Reports Second Quarter 2025 Financial ResultsEvogene Ltd. reported second quarter 2025 financial results, with first-half revenues of $3.2 million, up 40% year-over-year driven by higher seed sales from subsidiary Casterra, while operating expenses decreased 31% to $7.7 million and net loss narrowed to $7.7 million from $9.8 million. The company completed the sale of most of Lavie Bio's activities and the MicroBoost AI for Ag platform to ICL for $18.71 million in July 2025, and raised $4.4 million through an at-the-market equity facility in June 2025. Evogene is undertaking a strategic repositioning centered on its ChemPass AI platform, including workforce reductions of 30% at Evogene and 40% at AgPlenus, partnerships with Google Cloud and Tel Aviv University, and an 18-month operational runway.Icl-GroupWhat Is Regenerative Agriculture 2.0?The article defines Regenerative Agriculture 2.0 as the evolution of traditional sustainable farming through the integration of advanced AgTech, data science, and biological innovations to ensure scalability and quantifiable environmental impact. Key companies such as ICL, Agmatix, Lavie Bio, and CropX are highlighted for their roles in providing precision agronomy tools, AI-enabled biostimulants, and monitoring systems that facilitate carbon market participation and ESG compliance.iGrow NewsAI Computational Biology Platforms Transform Life Science Product DevelopmentIsrael-based Evogene has developed three proprietary AI computational biology platforms—MicroBoost AI, ChemPass AI, and GeneRator AI—to support product development in microbial solutions, small molecule discovery, and genomic modification, with subsidiaries Lavie Bio and Casterra deploying these technologies commercially across agriculture and biofuels. CEO Ofer Haviv outlined the company's ambition to develop its own pharmaceutical drug pipeline by 2030 using the ChemPass engine, while also addressing regulatory and public perception challenges facing GMO and genome editing technologies, particularly in Europe. The company positions itself as an AI-first organization that builds custom algorithms in-house rather than relying on third-party models.Icl-Group4 Key Agriculture Trends To Watch Closely In 2025The article outlines four key AgroTech trends for 2025: AI-driven precision farming, carbon utilization with remote sensing, regenerative agriculture, and breakthroughs in ag biotechnology. ICL is positioned as a central actor in this transformation, actively investing in and partnering with startups like Agrematch, Lavie Bio, and PlantArcBio to deploy these innovations.NoCamelsIIA Backs R&D By Startup Using Bacteria To Help Crops GrowLavie Bio, an Israeli agritech company based in Rehovot, has received a grant from the government's Israel Innovation Authority (IIA) to advance its MicroFermentor technology, which uses beneficial bacteria to help crops grow. The patented microbe formulation enables bacteria to multiply directly on plants, reducing application costs, extending shelf life, and improving viability after field application. The funding, awarded following positive initial experiments, will support the next phase of development toward commercialization of what Lavie describes as a breakthrough bacterial-based solution.